• In patients with a recent CV event (stroke or MI), how does clopidogrel compare to aspirin in the secondary prevention of stroke, MI, and CV death?


    • How clinically efficacious and safe is intra-arterial recombinant prourokinase in patients with acute stroke of less than 6 hours' duration caused by MCA occlusion?


    • In patients with cryptogenic stroke or TIA with a patent foramen ovale (PFO), does percutaneous PFO closure reduce the risk of a recurrent event?


    • Among patients with a recent ischemic stroke, how does combination aspirin-dipyridamole compare to clopidogrel in preventing recurrent stroke?


    • In patients with carotid artery stenosis, how does carotid artery stenting compare with carotid endarterectomy in terms of stroke, MI, and death?


    • In patients with a history of CVA (including ischemic or hemorrhage stroke, TIA or amaurosis fugax) does the use of perindopril +/- indapamide lead to decreased risk of future stroke?


    • In patients with acute ischemic stroke, does the administration of alteplase, a tissue plasminogen activator (tPA), reduce disability at 3 months?


    • In patients with prior stroke or TIA, does high-dose atorvastatin reduce the risk of recurrent stroke?


    • Does recombinant activated Factor VII reduce severe disability or death in acute intracerebral hemorrhage compared to placebo?

tPA for Acute Ischemic Stroke

    • Does intravenous t-PA within three hours of the onset of ischemic stroke improved clinical outcome at three months?


    • In patients with AF, is dalteparin safe and superior to aspirin in the prevention of recurrent strokes during the first 14 days after an acute ischemic stroke?


    • In patients with a prior non-embolic ischemic stroke, is warfarin superior to ASA for secondary prevention?


    • In patients with recent ischemic CVA or TIA, does clopidogrel plus aspirin reduce recurrent events when compared to clopidogrel alone?


    • In patients with a recent TIA or non-disabling stroke and intra-cranial artery stenosis of 50 to 99%, does medical treatment using warfarin improve mortality and decrease risk for further cerebrovascular events compared with ASA?


    • In patients with symptomatic stenosis, does CEA reduce risk of death or stroke?